How likely are you to recommend Redeye to a friend or colleague?
1
2
3
4
5
6
7
8
9
10
Not likely
Very likely
Not likely
1
2
3
4
5
6
7
8
9
10
Very likely
Message received
Thanks again for rating us!
SEARCH
Biovica: DiviTum to Stir Some Blood
2020-05-25
07:20
NE
Niklas Elmhammer
Premium Plan required to unlock
Unlock companies to access
more high quality research.
Redeye initiates coverage of cancer diagnostics firm Biovica with base case of SEK 24. The shares have spiked some 140 percent YTD on the back of increasing investor optimism ahead of a possible US launch next year. While we see room for a slight pull-back short-term, a potential marketing approval in the US for blood-based cancer diagnostic test DiviTum within the next 6-12 months is a major catalyst for significant further upside to our valuation. Ongoing clinical validation to complete the submission to the FDA could provide important clues already in the next few months.